1. Introduction
===============

Total-knee arthroplasty (TKA) is widely known as one of the most effective treatments for severe osteoarthritis of the knee.^\[[@R1]\]^ However, this surgery is prone to significant intraoperative and postoperative blood loss along with long operation times and large wound surfaces. Therefore, allogenic blood transfusions are often used in clinical practice.^\[[@R2]\]^ However, this method increases the risk of immunologic and nonimmunologic adverse effects, such as a higher rate of postoperative infection, intravascular hemolysis, transfusion-induced coagulopathy, renal impairment or failure, and even death.^\[[@R3]\]^ Many strategies, including regional anesthesia, autologous blood donations, autologous drain transfusions, and acute normovolemic hemodilution, have been used to reduce blood transfusion rates.^\[[@R4]\]^ However, the strategies' applications are limited by their clinical and financial efficacies and the fact that antifibrinolytic agents are needed to decrease blood loss.

Antifibrinolytic agents, including tranexamic acid (TXA), epsilon aminocaproic acid (EACA), and aprotinin, are widely used to reduce bleeding and for transfusions in cardiac, orthopedic, and hepatic surgeries.^\[[@R5],[@R6]\]^ TXA and EACA are synthetic amino acid derivatives that reversibly bind to plasminogen, thereby inhibiting fibrin binding and plasmin activation.^\[[@R7]\]^ Aprotinin, which is a naturally occurring, single-chain, 58-amino acid polypeptide, is a proteinase inhibitor that binds and inhibits plasmin.^\[[@R8]\]^ Numerous studies have investigated their efficacies in reducing blood loss and transfusion requirements in patients undergoing orthopedic surgery.^\[[@R9]\]^

Recent studies have suggested that antifibrinolytic agents are effective in reducing blood loss and blood transfusions in patients undergoing total-hip arthroplasty and spine surgery.^\[[@R10]\]^ Although these antifibrinolytic agents can reduce the perioperative bleeding of TKA, few prospective orthopedic studies directly compare these 3 agents. Therefore, we conducted this meta-analysis to investigate the effectiveness of antifibrinolytic agents (TXA, EACA, and aprotinin) and compare their benefits of intraoperative intravenous in reducing blood loss and blood transfusions for patients undergoing TKA.

2. Methods
==========

2.1. Study registration and ethical approval
--------------------------------------------

This review design was based on the methodology of the Cochrane Library in regards to conducting the meta-analysis. All of the data were reported according to the Quality of Reporting for Meta-analyses, which is provided by the Handbook for Systematic Reviews of Interventions (version 5.0).^\[[@R11]\]^ This meta-analysis was conducted in accordance with the guidance of the preferred reporting items and meta-analysis statements for systematic evaluation of interventions and the Cochrane manual. All analyses are based on previously published literatures and do not belong to studies with experimental human or animal subjects, so ethical approval and patient consent are not required.

2.2. Search strategy
--------------------

We identified the relevant studies that evaluated the use of antifibrinolytic agents in patients undergoing TKA. We searched PubMed, Embase, and the Cochrane Library (the search was last updated on August 2019) with a search algorithm based on a combination of the following seven factors. The search terms were listed as the following: "antifibrinolytics," "cyklokapron," "aprotinin," "tranexamic acid," "epsilon aminocaproic acid," "total knee arthroplasty," and "randomized controlled trials." The search was restricted to "humans" and the "English" language.

2.3. Selection criteria
-----------------------

Studies were included if they met the following criteria: participants who underwent TKA; randomly assigned patients to the treatment group who received antifibrinolytic agents and control patients who received a placebo or no treatment; neither the antifibrinolytic agent-treated group nor the control group used anticoagulant drugs before the operation; both groups reported one of the following outcomes: blood loss, the number of patients who received allogeneic transfusions, the number of blood transfusion units per patient, and the number of patients with deep vein thrombosis (DVT). And exclusion criteria for this study as follows: they were non-English language studies; they were nonrandomized controlled trials; randomized controlled trials that did not contain any of the above outcomes were also excluded. The initial electronic database retrieval that identified the potential studies for inclusion and that were based on title and abstract information were performed by two independent authors (QM, GH).

2.4. Data extraction
--------------------

Data extractions for the included studies were conducted by 2 independent authors (QM, GH). Any disagreement between the 2 authors was resolved by consensus or consultation with the senior author (TJ). For each report, the relevant information was extracted, including the name of first author, journal, country of origin, year of publication, studied population, study design (prospective or retrospective), patient enrollment procedure, sample size, study design, subject age, the type of surgery, the dose and timing of the antifibrinolytic agents, and outcome data. In addition, adverse outcomes were recorded. For studies without adverse outcomes, authors were contacted for confirmation or for more information regarding adverse events if necessary. Each eligible study was evaluated by 2 of the authors independently, and discrepancies were resolved by discussion with a 3rd author.

2.5. Risk of bias
-----------------

*I*^2^ statistics were used to evaluate the between study heterogeneity analysis in this meta-analysis. The heterogeneity among studies was tested by *I*^2^ statistic. As a guide, *I*^2^ values \<50% indicated moderated and \>50% indicated high heterogeneity.

2.6. Statistical analysis
-------------------------

All analyses were conducted using RevMan version 5.0 (The Nordic Cochrane Centre, The Cochrane Collaboration) with *P* \< 0.05 being considered statistically significant. The weighted mean difference (WMD) and 95% confidence interval (CI) via the use of the Mantel--Haenszel method were used for analysis of the continuous data, the risk ratio (RR) and 95% CI were applied for analysis of the dichotomous data. The data from each study were pooled by a fixed- or random-effects model based on the degree of heterogeneity.^\[[@R12]\]^ Heterogeneity across the included studies by using the value of *I*^2^ and the result of the Chi-squared test. Substantial heterogeneity was considered present when *P* \< .05 and an *I*^2^ value of \>50% were considered to be suggestive of statistical heterogeneity. A subgroup analysis was also performed to explore the heterogeneity.

3. Results
==========

3.1. Study selection and characteristics
----------------------------------------

A total of 479 abstracts and titles were reviewed. Of these abstracts and titles, 28 randomized controlled trials met the eligibility criteria and were included in this study^\[[@R13][@R14][@R15][@R16][@R17][@R18][@R19][@R20][@R21][@R22][@R23][@R24][@R25][@R26][@R27][@R28][@R29][@R30][@R31][@R32][@R33][@R34][@R35][@R36][@R37][@R38][@R39][@R40][@R41]\]^ (Fig. [1](#F1){ref-type="fig"}). Seventeen hundred and five patients were enrolled in the randomized controlled trials. The characteristics of the included studies are presented in Table [1](#T1){ref-type="table"}. In total, 28 studies involved TXA,^\[[@R13][@R14][@R15][@R16][@R17][@R18][@R19][@R20][@R21][@R22][@R23][@R24][@R25][@R26][@R27][@R28],[@R34],[@R40],[@R41]\]^ 2 studies involved aprotinin, and 1 study involved EACA.^\[[@R23]\]^ A total of 18 studies involved bleeding analyses,^\[[@R13][@R14][@R15][@R16],[@R18],[@R20],[@R21],[@R23][@R24][@R25][@R26][@R27],[@R31],[@R34]\]^ and 26 studies were included in the DVT analysis.^\[[@R13][@R14][@R15][@R16][@R17][@R18][@R19][@R20][@R21][@R22][@R23][@R24][@R25][@R26][@R27][@R28][@R29],[@R34]\]^ The characteristics of the included studies are presented in Table [1](#T1){ref-type="table"}.
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3.2. Risk of bias
-----------------

*I*^2^ statistics were used to evaluate the between study heterogeneity analysis in this meta-analysis. The heterogeneity among studies was tested by *Q* statistic and quantified by *I*^2^ statistic. As a guide, *I*^2^ values \<50% indicated moderated and \>50% indicated high heterogeneity.

3.3. Total blood loss
---------------------

Total blood loss was examined in 9 trials involving a total of 282 patients. The meta-analysis results showed that the use of antifibrinolytic agents significantly reduced total blood loss (WMD with 95% CI: −272.19, −338.25 to −206.4, *I*^2^ = 0%, random effect model) (Figs. [2](#F2){ref-type="fig"} and 3).
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3.4. Intraoperative blood loss
------------------------------

Five studies with a total of 244 patients were eligible for this meta-analysis. These randomized trials included 124 patients who received antifibrinolytic agents and 120 patients who received control treatments. The use of antifibrinolytic agents did not significantly reduced intraoperative blood loss (WMD with 95% CI: 2.67, −34.72 to 40.07, *I*^2^ = 0, fixed-effects model) (Figs. [4](#F4){ref-type="fig"} and 5).

![Forest plot of the intraoperative blood loss. CI = confidence interval, SD = standard deviation.](medi-99-e20214-g005){#F4}

![Funnel plot of the intraoperative blood loss. MD = mean difference, SE = standard error.](medi-99-e20214-g006){#F5}

3.5. Postoperative blood loss
-----------------------------

Three studies with a total of 170 patients were eligible for this meta-analysis. The use of antifibrinolytic agents reduced postoperative blood loss (WMD with 95% CI: −102.83, −157.64 to −46.02, *I*^2^ = 38, fixed-effects model) (Figs. [6](#F6){ref-type="fig"} and 7).
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3.6. Rate of blood transfusion
------------------------------

Data on transfusion rates were examined in 18 trials involving a total of 1227 patients. Antifibrinolytic agents significantly reduced the rate of blood transfusion (RR with 95% CI: 0.7, 0.12 to 0.24, *I*^2^ = 0, fixed-effects model) (Figs. [8](#F8){ref-type="fig"} and 9).
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3.7. Average blood transfusion units
------------------------------------

This outcome measure was available in 4 trials, which involved a total of 278 patients. The use of antifibrinolytic agents significantly reduced the average units of blood transfusions compared with the control group (WMD with 95% CI: −1.34, −1.47 to −1,21, *I*^2^ = 0, fixed-effects model) (Figs. [10](#F10){ref-type="fig"} and 11).
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3.8. Average blood transfusion volume
-------------------------------------

Two studies with a total of 150 patients reported mean transfusion volumes. The use of antifibrinolytic agents significantly reduced the average blood transfusion volume compared with the control group (WMD with 95% CI: −244.04, −284.89 to −203.19, *I*^2^ = 0, fixed-effects model) (Figs. [12](#F12){ref-type="fig"} and 13).
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3.9. Rate of DVTs
-----------------

Twenty-six trials with 1818 patients reported DVT complications. Patients receiving antifibrinolytic agents (n = 919) had 23 episodes of DVT, while 899 patients who did not receive antifibrinolytic agents had a total of 21 episodes of DVT. The rate of DVT was not associated with the use of antifibrinolytic agents when the group was compared with the control group (RR: 1.02; 95% CI: 0.58--1.81, *I*^2^ = 0, fixed-effects model) (Figs. [14](#F14){ref-type="fig"} and 15).
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![Funnel plot of the effect of antifibrinolytic agents on deep vein thrombosis. EACA = epsilon aminocaproic acid, RR = risk ratio, SE = standard error.](medi-99-e20214-g016){#F15}

4. Discussion
=============

The significant blood loss and risk for blood transfusions are important features that need to be considered in TKA.^\[[@R42]\]^ This requirement is a result of several factors that are inherent to the surgery itself, such as extensive bone decortication, fluid therapy-induced dilutional coagulopathy, and the presence of microthrombi in the transfusion blood.^\[[@R43]\]^ Previous studies have shown that approximately 38% patients undergoing TKA require blood transfusions for a total average blood loss of 1500 mL during the perioperative period.^\[[@R44]\]^ Many patients with tissue extravasation after TKA present with lower limb swelling, pain, and effects in functional exercise.^\[[@R45]\]^ Such techniques as autologous blood transfusions, intraoperative hemodilution, hypotensive anesthesia, and modern modified uses of drainage increase additional logistical problems and may be immunomodulatory.^\[[@R46]\]^

After that, the use of antifibrinolytic agents can avoid many of these complications and are widely available and inexpensive.^\[[@R6]\]^ Though published literature on antifibrinolytic agents has dramatically expanded over the past several years, the literature lacks a comprehensive review on the efficacy of antifibrinolytic agents in primary TKA. We performed a meta-analysis of different antifibrinolytic agents in the setting of TKA to investigate the variables associated with administration of antifibrinolytic agents as part of the supporting evidence for the combined clinical practice guidelines. In the early, Kagoma et al studied the effects of antifibrinolytic agents in reducing blood transfusions after total-knee and total-hip arthroplasties, and the authors reviewed the evidence for using TXA, aprotinin, and EACA in total blood loss and transfusion rates in orthopedic surgery.^\[[@R47]\]^

Our results showed that the use of antifibrinolytic agents (as well as subgroup analyses of TXA, EACA, and aprotinin) for patients undergoing TKA is effective in reducing blood loss and blood transfusions, as well as in reducing the units and volumes of transfusion, and did not appear to increase incidences of DVT. Statistically significant differences were observed in blood loss, transfusion requirements, and the number of transfusions between the antifibrinolytic agent-treated and control groups. Furthermore, the use of antifibrinolytic agents also reduced the probability of receiving a blood transfusion by 41%. Another, Tan et al performed a review of antifibrinolytic agents and found them to be effective and safe in total-hip arthroplasty.^\[[@R48]\]^ The evidence of the use of antifibrinolytic agents in reducing the need for blood transfusions is strong. However, according to the action mechanism of the antifibrinolytic agents, the increased risk of DVT is another concern in major orthopedic surgery.^\[[@R49]\]^

The TXA has been shown to be effective and safe in major orthopedic surgery.^\[[@R50]\]^ Aprotinin has been used in cardiac surgery and noncardiac procedures, including liver transplantations and major vascular reconstructions, and it is effective in reducing blood loss and blood transfusions.^\[[@R51],[@R52]\]^ Several studies have previously shown that aprotinin is effective in decreasing surgical blood loss in various orthopedic surgeries,^\[[@R53]\]^ then the European Medicine Agency recommended the lifting of the restrictions on the use of aprotinin.^\[[@R54]\]^

Compare with other studies, although a lot of research has been done so far, there are few prospective randomized controlled trials compare different antifibrinolytic agents in patients undergoing total-knee replacement. Recently, Boese et al reported the results of 194 TKA patients who were given TXA or EACA.^\[[@R55]\]^ Their study used tourniquets, but no drainage after surgery, and reported that TXA resulted in lower estimated blood loss. There was no need for blood transfusion in both groups, so the authors concluded that both TXA and EACA had clinical efficacy. Camarasa et al conducted a randomized controlled trial of 127 TKA patients, who were divided into TXA, EACA, and placebo groups.^\[[@R23]\]^ They found that total blood loss, changes in hemoglobin levels and transfusion rates were significantly lower in the 2 antifibrinolytic groups than in the placebo group. Our study with TKA patients is consistent with these studies. Our data support the view that postoperative loss (measured by postoperative drainage and blood volume loss) may higher in the EACA group compare with TXA and aprotinin, but does not lead to more blood transfusion.

At the same time, several limitations should also be acknowledged. First, we systematically searched a range of databases for published and unpublished trials. However, we cannot exclude the possibility that some studies were missed. If many unpublished trials showed little or no effect of the antifibrinolytic agents on the reduction of blood loss and transfusion requirements, the treatment effect of antifibrinolytic agents could be overestimated in this meta-analysis. Second, the funnel plot showed the presence of a publication bias in this meta-analysis. Publication bias is a well-known problem affecting the accuracy of the results of a meta-analysis because positive results tend to be accepted by journals, whereas negative results are often subjected to rejection and a lack of publication. Third, there was significant heterogeneity among the studies when considering intraoperative blood loss, postoperative blood loss, and blood units or volumes transfused per patient. Furthermore, the estimation of blood loss was variable because blood loss resulting from hematomas or tissue extravasations were rarely measured, which could cause inaccurate results. It is likely that these inconsistencies across all of the studies contributed to the high *I*^2^ values that were observed in the statistical analyses. Thus, more accurate results could be obtained if the total red blood cell loss could be calculated by using the reservoir\'s blood hematocrit levels and if a unified standard blood transfusion protocol was adopted. The other variations that may have accounted for such heterogeneity include differences in the surgical techniques, the sample sizes, and the variations in the patient characteristics. Thus, more high-quality, randomized controlled trial studies with large sample sizes and complete data are required for further meta-analyses to compare these antifibrinolytic agents.

Given the results of 1899 patients in this study, it can be concluded that these antifibrinolytic agents are equally safe and effective in preventing excessive bleeding during TKA surgery. Because of its low cost, EACA may be seen as a suitable alternative front-line agent to reduce the financial burden on healthcare providers. From the comparative advantage of economic and technical means, we can compare different antifibrinolytic agents in the future, so as to get more appropriate way for patients under TKA.

5. Conclusion
=============

Our research provides evidence that the use of antifibrinolytic agents may significantly reduce blood loss and blood transfusion requirements. Additionally, this analysis did not increase the risk of DVT in patients undergoing TKAs. Therefore, these findings support the routine use of antifibrinolytic agents in TKA. However, given the heterogeneity of the pooled estimates and the low number of studies, larger studies are needed to examine blood loss, transfusions, and thromboembolic complications in the use of antifibrinolytic agents during TKA. Considering the economic and technical problems, more research results need to be analyzed so as to provide better antifibrinolytic agents for patients under TKA.
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